Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Company Deals

Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam

Fineline Cube Jan 27, 2026
Company Deals

Insilico Medicine Partners with Qilu Pharma on AI Drug Development

Fineline Cube Jan 27, 2026
Company Deals

Acrobiosystems Files for Hong Kong IPO as Life Science Tools Leader

Fineline Cube Jan 27, 2026
Company Deals

Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease

Fineline Cube Jan 27, 2026
Policy / Regulatory

NMPA Suspends Two Indian Pharma APIs Over GMP Violations

Fineline Cube Jan 27, 2026
Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Fineline Cube Jan 28, 2026
Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Fineline Cube Jan 28, 2026
Company

Sanner Group Prepares to Open Second Manufacturing Facility in China

Fineline Cube Feb 6, 2023

Germany-based Sanner Group, a specialist in medical devices and pharma packaging, has announced plans to...

Company

Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi

Fineline Cube Feb 6, 2023

China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...

Digital Medical Device

Vertex’s MoDAS System Gains NMPA Approval for Movement Disorder Assessment

Fineline Cube Feb 6, 2023

China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA)...

Company Digital

BeiGene Launches Mental Health Program for Cancer Patients

Fineline Cube Feb 6, 2023

China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a...

Company Deals

AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics

Fineline Cube Feb 6, 2023

Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...

Company Drug

Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment

Fineline Cube Feb 6, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...

Company Deals

Forlong Biotechnology Secures Series A Funding for Protein Drug Development

Fineline Cube Feb 6, 2023

Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...

Company Deals

Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06

Fineline Cube Feb 6, 2023

Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...

Company Deals

Haisco Pharmaceutical Announces Public Offering for Clinical Studies

Fineline Cube Feb 6, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering...

Company Drug

BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review

Fineline Cube Feb 6, 2023

Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...

Company Drug

JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course

Fineline Cube Feb 6, 2023

Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...

Company Deals

Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440

Fineline Cube Feb 6, 2023

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...

Company Drug

Mabwell’s Novel ADC 9MW2921 Accepted for NMPA Review

Fineline Cube Feb 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...

Company

Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth

Fineline Cube Feb 6, 2023

US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...

Company

GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift

Fineline Cube Feb 6, 2023

UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year...

Policy / Regulatory

China’s NMPA Releases 64th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Feb 3, 2023

China’s National Medical Products Administration (NMPA) has released the 64th batch of reference drugs for...

Company Drug

Bristol-Myers Squibb’s Ozanimod Approved in China for Multiple Sclerosis

Fineline Cube Feb 3, 2023

Bristol-Myers Squibb (BMS, NYSE: BMY) has announced receiving marketing approval from China’s National Medical Products...

Company

Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales

Fineline Cube Feb 3, 2023

Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...

Company

Merck & Co. Posts 22% YOY Sales Growth; Keytruda and Gardasil Drive Revenues

Fineline Cube Feb 3, 2023

Merck & Co. (NYSE: MRK) has released its Q4 and full-year 2022 financial report, showcasing...

Company

Takeda Posts Strong Q3 Results, Announces Pipeline Advances in Oncology and Rare Diseases

Fineline Cube Feb 3, 2023

Japan-based pharmaceutical giant Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...

Posts pagination

1 … 515 516 517 … 615

Recent updates

  • Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials
  • Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal
  • IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform
  • Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials
  • Nanjing Leads Biolabs Secures FDA Fast Track for LBL-034 in Multiple Myeloma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Company Drug

Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.